Uppsala University
Breast Cancer Study Informs Affibody, GE HealthCare's Development Path for HER2 Radiopharmaceutical
Premium
The PET imaging agent 68Ga-ABY-025 could have a leg up over IHC in predicting metastatic breast cancer patients' ability to respond to HER2-targeted treatment.